Health 1 April 2026 The Observer (Uganda)
Unpacking Lenacapavir: Uganda's New HIV Prevention Tool Amid Hidden Challenges
Uganda has received its first shipment of 19,200 doses of Lenacapavir, a highly effective long-acting HIV prevention injection approved for PrEP use. While it offers twice-yearly dosing with over 99.9% efficacy against HIV-1, experts highlight critical drug interactions, side effects, and supply limitations that demand careful management. Source: https://observer.ug/news/the-hidden-complexities-of-hivs-lenacapavir
Introduction to Lenacapavir
Uganda welcomed its initial batch of 19,200 Lenacapavir doses on February 24, 2026, backed by the Global Fund. Produced by Gilead Sciences, this FDA-approved injectable serves as a convenient PrEP option, administered just once every six months to block HIV infection.
High Efficacy with Limitations
Clinical trials confirm Lenacapavir’s exceptional performance, exceeding 99.9% effectiveness against HIV-1, the dominant strain in Uganda comprising 95% of global cases. However, it fails against HIV-2, prevalent in regions like West Africa. For treatment, it requires combination with other antiretrovirals to prevent resistance, meaning users might still need daily pills.
Drug Interactions and Side Effects
Significant concerns arise from interactions, particularly with rifampicin, a key TB treatment drug common among HIV patients. Rifampicin lowers Lenacapavir levels, risking HIV vulnerability. Strategies include completing TB therapy first, using dose boosts, or switching to rifabutin.
Other conflicts involve certain antifungals, statins, and erectile dysfunction drugs like Viagra. Residual drug effects can linger up to nine months post-injection. Common reactions include injection-site swelling, pain, nausea, diarrhea, headaches, and potential immune reconstitution issues.
Expert Perspectives
Dr. Flavia Matovu Kiweewa from Makerere University-Johns Hopkins notes that side effects like nodules at injection sites are mild and temporary, deeming them a minor trade-off for potent protection against resistant HIV-1 strains. CDC Uganda’s Dr. Mary Boyd stresses avoiding co-administration with TB regimens, opting for counseling and alternatives. Officials affirm supply coordination with the Ministry of Health under U.S.-Uganda agreements.
Supply and Access Hurdles
With over 1.5 million Ugandans living with HIV and 38,000 new infections yearly, the arriving doses are insufficient. Pricing around $40 post-subsidies and voluntary licensing may restrict broader access, echoing uncertainties in Zambia and Zimbabwe.
Source: The Observer (Uganda)